Evidence Table 75. KQ2—Continuous data—C-reactive protein

| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Mabuchi 200739  parallel | Unclear | atorvastatin | 1 | Coenzyme Q10. | 24 | NR | Mean: 799  Median  SD: 1209  SE:  Lower:  Upper: | Mean:  % mean: -46.8  Median:  SD:  0.5408  P: | Mean:  Median:  SD:  P: | There's no significant differences between groups (p=0.5943). Several other continuous outcomes, such as alkaline phosphatase, LDH, CoQ10/ total cholesterol and CoQ10/LDL were not extracted. | medium |
|  | Placebo | 25 | Mean:777  Median  SD: 1038  SE:  Lower:  Upper: | Mean:  % mean: -14.6  Median:  SD:  P:  0.8743 |

| Evidence Table 75. KQ2—Continuous data—C-reactive protein (continued) | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Author Year**  **Study Design** | **CHD Risk Category** | **CVD drug** | **Dose** | **Supplement/ Control** | **N** | **Definition of outcome** | **Post treatment Mean/**  **(Median)**  **SD/SE**  **Lower limit (IQR, 95% CI)**  **Upper Limit (IQR, 95% CI)** | **Mean change/ % change from baseline/**  **SD/**  **P Value** | **Between group differences in Means/ medians**  **SD/**  **P Value** | **Summary of Results** | **Overall Risk of Bias (ROB) Assessment** |
| Budoff 200410  parallel | At high risk for CHD | statins + aspirin | 10-40 | Garlic | 9 | measured after 12 hr fast at 800 hr | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:-0.1  % mean:  Median:  SD:  0.22  P: | Mean:  Median:  SD:  P:  0.8464 |  | medium |
|  | Placebo | 10 | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:-0.13  Median:  SD:  0.27  P: |
| Chan 200212  parallel | At moderate/moderately high risk for CHD (2+ risk factors) | atorvastatin | 40 | Fish/marine oils. | 11 | 12 hr fasting at 800hr | Mean: 1.14  Median  SD: 1.97  SE:  Lower: 0.6  Upper: 2.4 | Mean:  % mean:  Median:  SD:  P: | Mean:  Median:  SD:  P: |  | medium |
|  | Placebo | 13 | Mean:  Median  SD:  SE:  Lower: 1.1  Upper:4 | Mean:  Median:  SD:  P: |
| Desideri 200318  parallel | At low risk for CHD (0-1 risk factors) | Simvastatinstatin, Bezafibrate | simvastatinstatin: 40; Bezafibrate: 800 | Vitamin E. |  | Measured after 12 hr fast | Mean: 1.5  Median  SD: 0.4  SE:  Lower:  Upper: | Mean:  % mean:  Median:  SD:  P:  <0.05 | Mean:  Median:  SD:  P: | I assumed no losses to follow-up although I did not see this explicitely stated. Baseline data also given. | medium |
|  | No treatment (aside from CVD drug) |  | Mean:1.9  Median  SD: 0.3  SE:  Lower:  Upper: | Mean:  Median:  SD:  P:  <0.05 |
|  |  |  | Mean:  Median  SD:  SE:  Lower:  Upper: | Mean:  Median:  SD:  P: |